"Hypolipidemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.
| Descriptor ID |
D000960
|
| MeSH Number(s) |
D27.505.519.186.071 D27.505.954.557.500
|
| Concept/Terms |
Hypolipidemic Agents- Hypolipidemic Agents
- Agents, Hypolipidemic
- Antihyperlipidemics
- Hypolipidemic Drugs
- Drugs, Hypolipidemic
- Antilipemic Drugs
- Drugs, Antilipemic
- Antilipemics
- Antihyperlipemics
- Antilipemic Agents
- Agents, Antilipemic
|
Below are MeSH descriptors whose meaning is more general than "Hypolipidemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypolipidemic Agents".
This graph shows the total number of publications written about "Hypolipidemic Agents" by people in this website by year, and whether "Hypolipidemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 2 | 4 |
| 2004 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2012 | 3 | 1 | 4 |
| 2013 | 1 | 1 | 2 |
| 2014 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypolipidemic Agents" by people in Profiles.
-
Lipid-Lowering Drug Gemfibrozil Protects Mice from Tay-Sachs Disease via Peroxisome Proliferator-Activated Receptor a. Cells. 2023 Dec 08; 12(24).
-
HDL-Targeted Therapies During Myocardial Infarction. Cardiovasc Drugs Ther. 2019 06; 33(3):371-381.
-
Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis. J Neurochem. 2017 05; 141(3):423-435.
-
Guidelines for a new year. Am J Ther. 2014 Jan-Feb; 21(1):1.
-
Effectiveness of a pharmacy care management program for veterans with dyslipidemia. Pharmacotherapy. 2013 Jul; 33(7):736-43.
-
Moderate therapeutic hypothermia in a patient with acute pancreatitis: case report and review of the literature. Pancreas. 2013 Apr; 42(3):544-5.
-
Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor a: implications for late infantile Batten disease therapy. J Biol Chem. 2012 Nov 09; 287(46):38922-35.
-
Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-?. J Biol Chem. 2012 Oct 05; 287(41):34134-48.
-
Gemfibrozil, a lipid-lowering drug, upregulates IL-1 receptor antagonist in mouse cortical neurons: implications for neuronal self-defense. J Immunol. 2012 Jul 15; 189(2):1002-13.
-
Gemfibrozil, a lipid-lowering drug, induces suppressor of cytokine signaling 3 in glial cells: implications for neurodegenerative disorders. J Biol Chem. 2012 Aug 03; 287(32):27189-203.